(Q81638797)
Statements
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors (English)
A A Desai
R L Schilsky
A Young
L Janisch
W M Stadler
N J Vogelzang
S Cadden